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ABSTRACT: Proteomics of human milk has been used to identify
the comprehensive cargo of proteins involved in immune and
cellular function. Very little is known about the effects of gestational
diabetes mellitus (GDM) on lactation and breast milk components.
The objective of the current study was to examine the effect of
GDM on the expression of proteins in the whey fraction of human
colostrum. Colostrum was collected from women who were
diagnosed with (n = 6) or without (n = 12) GDM at weeks 24−
28 in pregnancy. Colostral whey was analyzed for protein
abundances using high-resolution, high-mass accuracy liquid
chromatography tandem mass spectrometry. A total of 601 proteins
were identified, of which 260 were quantified using label free
spectral counting. Orthogonal partial least-squares discriminant
analysis identified 27 proteins that best predict GDM. The power law global error model corrected for multiple testing was used
to confirm that 10 of the 27 proteins were also statistically significantly different between women with versus without GDM. The
identified changes in protein expression suggest that diabetes mellitus during pregnancy has consequences on human colostral
proteins involved in immunity and nutrition.
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■ INTRODUCTION
In addition to nutrients, breast milk delivers bioactive proteins
that possess a wide range of biological activities that promote
the normal development and maturation of the innate immune
system.1 Bioactive proteins in human milk exert protection
against infectious diseases via antimicrobial and immunomo-
dulatory activities that confer passive immunity to the breastfed
infant.1,2 For example, secretory immunoglobulin A (sIgA), the
predominant immunoglobulin in human milk,3 provides
protection to neonates by coating microorganisms, inhibiting
colonization, and neutralizing viral and bacterial endotoxins.1
Interestingly, the metabolic state of the mother during
pregnancy has been found to influence the expression of
protective proteins in breast milk. Concentrations of
immunoglobulins IgA and IgG4,5 and complement C3 protein5
were lower in colostrum of women with hyperglycemia versus
normoglycemic women, which suggests a link between
maternal insulin sensitivity and the immune functions of
milk. Gestational diabetes mellitus (GDM), a complex disease
characterized by elevated blood glucose,6 has immediate and
lasting metabolic and immune consequences in infants exposed
to maternal diabetes in-utero.7−9 For example, the concen-
tration of sIgA and its glycosylation in breast milk collected at
14 days postpartum was significantly lower in women with
versus without GDM.10
Proteomic profiling of milk using high-sensitivity, label-free,
semiquantitative mass spectrometry is a potentially useful
diagnostic tool to reveal the multifunctional properties of
milk,11−14 the health state of the lactating mother,15 and effects
in the breastfed infant.16 For example, changes in 75 low
abundance proteins in milk were identified as potential
biomarkers of mastitis in dairy cows.15 Recently, Molinari et
al. identified 55 differentially expressed proteins between
pooled skim milk from mothers delivering at term versus
preterm, which suggests that mammary development during
pregnancy influences protein synthetic and transport pathways
in lactation;17 however, the proteomic analysis of breast milk
from women with metabolic dysregulation during pregnancy
such as GDM has not been reported.
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The objective of this study was to determine the effects of
GDM on the proteome of human whey colostrum. We
hypothesized that proteins involved in immune function found
in colostral whey would be different between women with
GDM compared to women without GDM. In the current study,
whey was isolated from human colostrum collected from
women with and without GDM and analyzed by high-
resolution, high-mass accuracy liquid chromatography tandem
mass spectrometry (LC−MS/MS). The findings reported
herein document for the first time differences in colostral
whey due to GDM in mothers and illustrate the potential for
the characterization of milk for immune, metabolic, and
developmental functions.
■ MATERIALS AND METHODS
Subject Enrollment
Colostrum samples from primiparous and multiparous women
who gave birth to term infants and were diagnosed with (n = 6)
or without GDM (n = 12) were prepared and analyzed for this
study. Primiparous women have only given birth to one infant,
and multiparous women have given birth to two or more
infants. GDM was screened for during each subjects’ routine
24−28 week prepartum clinical visit using a 50 g 1 h oral
glucose tolerance test (OGTT). Subjects whose 1 h OGTT was
less than 7.8 mmol/L comprised the normal glycemic subject
pool (non-GDM). Subjects whose 1 h OGTT exceeded 7.8
mmol/L completed a 3 h 100 g OGTT for a final GDM
diagnosis. During pregnancy, two of the subjects with GDM
controlled their blood sugar with diet, two with diet and oral
insulin sensitizing medications, and two with insulin.
Milk Sample Collection and Processing
Colostrum samples were collected between the first and third
day of life postpartum by hand expression from one breast by
the subject with assistance by an International Board Certified
Lactation Consultant and frozen immediately in subjects’
homes or transported to the lab on ice and stored at −80 °C.
Samples from each subject were analyzed independently
without pooling. Anthropometric and health history and status
upon collection were obtained from self-reported health history
questionnaires. Samples were deidentified to protect patient
privacy and ensure blinding during proteomic analysis. The
West Virginia University and University of California Davis
Institutional Review Boards approved all aspects of the study,
and informed consent was obtained from all subjects. This trial
was registered on clinicaltrials.gov (ClinicalTrials.gov, identifier:
NCT01817127).
Protein Extraction
When thawed, 5 μL of protease inhibitor (Roche, complete
mini EDTA-free, 50× stock) was added to each individual 250
μL colostrum sample. Colostrum sample volumes ranged from
70−250 μL. Casein was depleted with the addition of CaCl2 to
adjust the final calcium concentration to 0.06 M. The pH was
adjusted to 4.6, and samples were incubated at room
temperature for 1 h.18 The samples were centrifuged at 13
000 × g at 4 °C for 30 min twice, and 100 μL of aqueous
middle whey fraction was collected. The proteins were
precipitated, and lipids in the whey were removed using the
Wessel and Flügge method.19 In brief, methanol−chloroform−
water was added to the whey samples prior to several
centrifugation steps. The supernatant containing the lipids
was then discarded, and the protein pellet was resuspended in
50 mM ammonium bicarbonate up to 1:4 (v/v) and sonicated
in 15 min intervals until the pellet was fully solubilized in
solution. Protein concentrations were determined using
NanoDrop spectrophotometer (ND-1000 Spectrophotometer,
NanoDrop, Wilmington, DE), and 5 μL of the same protease
inhibitor was added to each sample prior to freezing overnight
at −80 °C. On the following day, thawed samples (at room
temperature) were measured for their protein concentrations
using the NanoDrop spectrophotometer. Sample volumes were
adjusted to contain 100 μg of whey protein.
In-Solution Digestion
Whey protein samples were digested in-solution using a
modified standard trypsin digestion protocol.13 Briefly,
acetonitrile (100%) (ThermoFisher Scientific, Waltham, MA)
was added to each sample for a final concentration of 6% in 50
mM ammonium bicarbonate prior to protein reduction with
tris(2-carboxyethyl)-phosphine (TCEP) (Pierce, Rockford, IL)
and alkylation with iodoacetamide (Sigma Life Sciences, St.
Louis, MO), followed by treatment with dithiothreitol (Acros
Organics, Fair Lawn, NJ). Lactose was removed from the
samples using Amicon dialysis membrane with a molecular
cutoff of 3000 (Millipore, Billerica, MA) in ammonium
bicarbonate (50 mM). The samples were treated with
reductively methylated trypsin20 at a 1:30 enzyme-to-protein
ratio (w/w) overnight at room temperature. The digested
samples were centrifuged at 13 000 × g at room temperature
for 2 min, and the supernatant was dried in a speed vacuum and
resuspended in Milli-Q water (18.2 MΩ; Millipore, Billerica,
MA) prior to being desalted with Aspire RP30 desalting tips
(Thermo Fisher Scientific, Inc., Waltham, MA). The desalted
peptides were dried under speed vacuum and dissolved in 2%
ACN/0.1% TFA for LC−MS/MS analysis.
LC−MS/MS
LC separation was done on a Proxeon Easy-nLC II HPLC
(Thermo Scientific) with a Proxeon nanospray source. The
digested peptides were reconstituted in 2% acetonitrile/0.1%
trifluoroacetic acid, and duplicates of 3 μg of each sample were
loaded onto a 100 μm × 25 mm Magic C18 100 Å 5U reverse
phase trap where they were desalted online before they were
separated using a 75 μm × 150 mm Magic C18 200 Å 3U
reverse phase column. Peptides were eluted using a gradient of
0.1% formic acid (A) and 100% acetonitrile (B) with a flow rate
of 300 nL/min. A 90 min gradient ran with 5−35% B over 70
min, 35−80% B over 8 min, 80% B for 1 min, 80−5% B over 1
min, and finally held at 5% B for 10 min. Each of the gradients
was followed by a 1 h column wash.
Mass spectra were collected on an Orbitrap Q-Exactive mass
spectrometer (Thermo Fisher Scientific) in a data-dependent
mode with one MS precursor scan followed by 15 MS/MS
scans. A dynamic exclusion of 60 s was used. MS spectra were
acquired with a resolution of 70 000, and a target of 1 × 106
ions or a maximum injection time of 2 ms. MS/MS spectra
were acquired with a resolution of 17 500 and a target of 5 ×
104 ions or a maximum injection time of 60 ms. Peptide
fragmentation was performed using higher-energy collision
dissociation (HCD) with a normalized collision energy (NCE)
value of 27. Unassigned charge states as well as +1 and ions >
+5 were excluded from MS/MS fragmentation.
Database Searching
Tandem mass spectra were extracted, and charge states were
deconvoluted and deisotoped. All MS/MS samples were
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analyzed using X! Tandem (The GPM, thegpm.org; version
CYCLONE (2013.02.01.1)). X! Tandem was set up to search
the Uniprot Human reference database (May 2013, 20 252
entries) with an equal number of reverse sequences and 47
nonhuman common laboratory contaminant proteins from the
common Repository of Adventitious Proteins database (http://
www.thegpm.org/crap/), assuming the digestion enzyme
trypsin. X! Tandem was searched with a fragment ion mass
tolerance of 20 PPM and a parent ion tolerance of 20 PPM.
Carbamidomethyl of cysteine was specified in X! Tandem as a
fixed modification. Dehydration of the N-terminus, glu→ pyro-
Glu of the N-terminus, ammonia loss of the N-terminus, gln→
pyro-Glu of the N-terminus, deamidation of asparagine and
glutamine, oxidation of methionine and tryptophan, dioxidation
of methionine and tryptophan, and acetylation of the N-
terminus were specified in X! Tandem as variable modifications.
Criteria for Protein Identification
Scaffold (version Scaffold 4.0.0, Proteome Software Inc.,
Portland, OR) was used to validate MS/MS based peptide
and protein identifications. Peptide identifications were
accepted if they could be established at greater than 87.0%
probability by the Scaffold local false discovery rate (lFDR)
Naıv̈e Bayes classifier algorithm, with a minimum of two
identified peptides per protein. Protein probabilities were
assigned by the Protein Prophet algorithm.21 Proteins
containing similar peptides that could not be resolved by
MS/MS were grouped into clusters to satisfy the principles of
parsimony. By using these parameters, a peptide decoy false
discovery rate was calculated as 0.27% on the peptide level and
4.9% on the protein level.
Spectral Counting and Shared Peptide Refinement
Scaffold 4.0.0, was used to sum and normalize the spectral
counts and group peptides into proteins. Label-free quantita-
tion was performed on normalized total spectral counts for each
protein. Scaffold 4.0.0 normalizes total spectral counts for each
protein by multiplying the unweighted spectral counts for each
protein in each sample by the ratio of the average total
unweighted spectral counts in all samples and the total
unweighted spectral counts in each sample. Proteins were
retained in the final data analysis if >0 normalized total spectral
counts were found in ≥ 50% of the samples collected from
women with GDM or without GDM.
Statistical Analysis of Subject Characteristics
Anthropometric measurements were checked for normality
using SPSS version 22.0 for Windows (SPSS, Chicago, IL) and
transformed appropriately. To determine differences for
anthropometric measurements between women with versus
without GDM, normalized data were analyzed by independent
samples t test, and data that could not be normalized were
analyzed by Mann−Whitney U test (α = 0.05).
Orthogonal Partial Least Squared Discriminant Analysis
An orthogonal signal corrected partial least-squares discrim-
inant (O-PLS-DA)22,23 model was developed to identify the
top 10% of all differentially expressed proteins between women
with and without GDM. Modeling was conducted on protein
abundance expressed as normalized spectral abundance factors
(NSAF), adjusted for the time of colostrum collection, mean
centered, and scaled to unit variance. Leave-one-out cross-
validation was used to fit a preliminary two latent variable (LV)
O-PLS-DA model to discriminate between women with and
without GDM, and model scores and loadings were used for
feature selection. Features (proteins) were selected based on
their fulfillment of two criteria: (1) NSAF spectral counts were
significantly correlated with the O-PLS-DA model scores24
(Spearman’s rho, P ≤ 0.05); and (2) the absolute value of the
model loadings on the first latent variable 1 (LV1) ≥ 90th
quantile,25 where LV1 is the model component that captures
the maximum difference between colostral whey proteins from
women with and without GDM.
The classification performance of the selected and excluded
feature models were validated and compared using Monte
Carlo cross-validation (MCCV)26 and permutation testing.
MCCV was carried out by randomly selecting 2/3 of the
subjects as a training set (to build models) and using 1/3 of the
subjects to test the models, whil the proportion of women with
and without GDM was maintained in the full data set. This
procedure was repeated 100 times and used to estimate
distributions for the model performance statistics, fit to training
data (Q2), area under the receiver operator characteristic curve
(AUC), sensitivity (true positive rate), and specificity (true
negative rate). Permutation testing (prediction of randomly
assigned phenotype labels) was combined with the described
MCCV model cross-validation and used to estimate the
probability of achieving the model’s predictive performance
by chance, through comparison of the actual model Q2, AUC,
sensitivity, and specificity to those of the null hypothesis as
defined by the permuted models. Independent sample t tests
were used to asses O-PLS-DA model significance through
comparison of actual to permuted model and between selected
and excluded feature model’s performance statistics.
Power Law Global Error Model
The power law global error model (PLGEM), a parametric test
successfully applied to protein spectral counts27 and tran-
scriptomic data,28 was used to test for significant differences
(FDR adjusted P ≤ 0.05) in proteins identified by O-PLS-DA.
PLGEM was carried out on time (h) of postpartum colostrum
collection-adjusted NSAF protein abundances. All women were
classified into early (<20 h, n = 6) or late (>20 h, n = 12)
postpartum colostrum collection groups. A linear model was fit
to NSAF protein abundances from early and late colostrum
collection groups, and the residuals were then tested for
significant differences between GDM and non-GDM using
PLGEM. The significance level for the PLGEM test statistic
(i.e., P-values) was adjusted for the false discovery rate
associated with the multiple hypothesis testing according to
Benjamini and Hochberg29 and is reported as Padj.
Gene Ontology Enrichment Analysis
Gene ontology (GO) enrichment analysis was conducted using
the AmiGO v1.8,30 the GO consortium’s annotation and
ontology toolkit (GO database release 2014−01−04), using the
GO Term Enrichment tool.31 All differentially expressed
proteins between colostral whey from women with versus
without GDM (PLGEM, Padj ≤ 0.05) were evaluated for
enrichment in GO terms for biological processes, molecular
functions, and cellular components. All identified proteins were
used as a background set. Significantly overrepresented terms
were identified using the hypergeometric test (P ≤ 0.05).
Protein−Protein Interaction Network
A Gaussian graphical Markov network was calculated to model
empirical protein−protein interactions among all O-PLS-DA
selected colostral whey proteins that were differentially
expressed between women with and without GDM. To limit
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the scope of the partial correlation analysis to the strongest
protein−protein empirical relationships, q-order partial corre-
lations32 were first calculated to identify direct from indirect
protein associations. Q-order partial correlations (q = 1, 5, 8,
12) were calculated using 1000 replications each and used to
estimate the average nonrejection rate (β) for all pairwise
relationships. Analysis of the relationship between vertex
number, edge degree (connections), and β was used to select
β = 0.6 for edge acceptance. Coefficients of partial correlation
and P-values were calculated for all q-value identified
connections. Cytoscape33 was used to visualize all conditionally
independent empirical protein−protein interactions (P ≤ 0.05).
All multivariate and statistical analyses on proteomics data were
conducted in R v3.0.1.34
■ RESULTS
Subjects
All women in the study gave birth to healthy singleton term
infants. Upon colostrum collection, women did not report
illness or mastitis. Subject characteristics are reported in Table
1. Of the anthropometric measurements reported in Table 1,
only maternal prepregnancy weight and BMI were significantly
higher in women with versus without GDM (P < 0.01).
Additionally, colostrum was collected significantly sooner after
birth in women with versus without GDM (P < 0.05) (Table
1).
Characterization of Whey Proteins in Human Colostrum
Isolation of the aqueous whey fraction of colostrum collected
between the first and third day of life postpartum was
conducted by a series of centrifugation, casein precipitation,
and fat removal. Peptide identifications were accepted if they
could be established at greater than 87.0% probability by the
Scaffold Local FDR algorithm, with a minimum of two
identified peptides per protein and 4.9% protein FDR, which
corresponded to a 0.27% peptide decoy FDR for peptide
identification. After decoy peptides and proteins with nonhu-
man accessions were excluded, 601 proteins were identified in
colostral whey samples isolated from women with and without
GDM (Table 1, Supporting Information). These 601 identified
proteins were filtered to only include peptide species with >0
normalized spectral counts in ≥ 50% of the samples collected
from women with GDM or without GDM. With this
procedure, 60% of the originally measured 601 proteins were
removed, and 260 final proteins were retained for further
statistical and multivariate data analysis.
Identification of Differentially Expressed Colostral Whey
Proteins between Women with versus without Maternal
Gestational Diabetes Mellitus
O-PLS-DA, a multivariate classification model, was used to
identify the top 10% (n = 27) of all protein discriminants
between women with and without GDM (Table 1, Supporting
Information). The limited study sample size precluded the use
of a single hold-out test set for model validation, and instead,
100 rounds of MCCV were used to generate robust model
performance statistics (Table 2, Supporting Information). O-
PLS-DA scores from a model based on the 27 selected variables
demonstrate clear visual separation between the two
phenotypes (Figure 1). Of these 27 proteins, three were
correlated with maternal prepregnancy BMI: alpha-2-HS-
glycoprotein (Spearman’s rho = −0.61, P < 0.01), complement
C1r subcomponent-like protein (Spearman’s rho = −0.49, P <
0.05), and transmembrane protein 201 (Spearman’s rho = 0.48,
P < 0.05).
The prediction of maternal phenotype using the 27 selected
proteins was compared to the classification performance of a
model based on all excluded proteins (n = 233) and validated
using MCCV and permutation testing. Comparison of model
classification performance metrics (Q2, AUC, sensitivity, and
specificity) were used to asses model significance. On the basis
of test/training and permutation testing, the selected O-PLS-
DA model displayed significantly higher classification perform-
ance (P < 0.05) for the test set (AUC = 0.791 ± 0.14) than did
both the permuted model (random chance) (AUC = 0.475 ±
0.21) and a model using all 233 excluded proteins (AUC =
0.370 ± 0.19) (Table 2, Supporting Information). On the basis
Table 1. Subject Characteristics of Women with and without Gestational Diabetes Mellitus
Characteristics non-GDM (n = 12) GDM (n = 6)
mean ± SD min max mean ± SD min max
maternal age (y) 34.7 ± 2.1 32.0 39.0 34.5 ± 3.4 31.0 40.0
maternal height (m) 1.6 ± 0.1 1.5 1.8 1.6 ± 0.1 1.5 1.7
maternal prepregnancy weight (kg)a 59.2 ± 5.6 51.4 68.0 83.1 ± 19.3 63.5 113.6
maternal prepregnancy BMI (kg/m2)a 22.0 ± 1.4 20.1 25.0 31.6 ± 7.6 22.6 43.0
gestational age of infant (wk) 39.4 ± 1.3 37.0 41.5 38.5 ± 0.8 37.0 39.0
infant birth weight (g) 3.4 ± 0.3 2.9 3.9 3.5 ± 0.4 3.1 4.0
collection of colostrum postdelivery (h)b 57.8 22.9 9.0 77.0 28.2 30.4 4.6 74.0
Frequencies
Parity
primiparous 6 1
multiparous 6 5
Delivery Mode
c-section 1 1
vaginal 11 5
Infant Sex
female 6 2
male 6 4
aDifferent between non-GDM and GDM; log-transformed, independent samples t test, P < 0.01. bDifferent between non-GDM and GDM;
independent samples t test, P < 0.05.
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of PLGEM statistical analysis, with adjustment for time of
collection and multiple hypothesis testing, 10 of the 27 O-PLS-
DA selected proteins were significantly different between
women with versus without GDM (Table 2). Colostral whey
from women with GDM contained higher abundances of
apolipoprotein D, Ig heavy chain V−II region ARH-77, and
prostasin and lower abundances of alpha-2-HS-glycoprotein,
apolipoprotein A1 and E, 14−3−3 protein zeta/delta, protein
disulfide-isomerase, protein DJ-1, and protein FAM3D (Table
2).
Gene Ontology Enrichment Analysis
The 10 expressed colostral whey proteins that were significantly
different between women with and without GDM were
enriched (P < 0.05) for the biological process associated with
the “regulation of transport” (GO:0051049). No other GO
terms were statistically enriched.
Protein−Protein Dependency Network
The colostral whey proteins selected by O-PLS-DA were used
in a protein−protein interaction network to identify direct
empirical relationships (partial correlations, P ≤ 0.05) among
all 27 proteins (Figure 2). Nineteen of the 27 proteins were
directly correlated, of which 17 were positively and two were
negatively associated with one another. Sixteen proteins were
lower and three were higher in colostral whey from women
with GDM compared to women without GDM (Figure 2 and
Table 1, Supporting Information). Of the 19 associated
proteins, only seven were significantly different (PLGEM, P <
0.05) between colostral whey from women with versus without
GDM (14−3−3 protein zeta/delta, alpha-2-HS-glycoprotein,
apolipoprotein A1, apolipoprotein D, Ig heavy chain V−II
region ARH-77, protein disulfide-isomerase, and protein
FAM3D).
■ DISCUSSION
LC−MS/MS Approach
Proteomic profiling of milk using high-sensitivity, label-free,
semiquantitative mass spectrometry has revealed multifunc-
tional properties of milk and its dynamic nature to meet the
immunologic, metabolic, and developmental demands of the
neonate.11−14 Recently, a focus on the proteins of least
abundance in breast milk has received attention for their
unique bioactive roles in infant immunity, development, and
growth. By using ProteoMiner to enrich low abundance
proteins coupled with LC−MS/MS, Liao et al. identified a
total of 115 proteins in human whey, of which 35% were
involved in the immune response, and several proteins were
differentially regulated between early and mature milk.13 By
using ion-exchange and SDS-PAGE based protein fractionation
methods followed by LC−MS/MS, Gao et al. identified 976
Figure 1. Scores plot displaying discrimination between women with
and without GDM based on 27 selected colostral whey proteins using
orthogonal signal correction partial least-squares discriminant analysis.
Edge width and color encode the magnitude and direction of partial
correlations (P < 0.05) among all selected proteins based on O-PLS-
DA. Vertex size and shape display the magnitude and direction of the
fold-difference in protein expression in colostral whey from women
with GDM relative to women without GDM (mean GDM/mean non-
GDM). Significantly differentially expressed proteins (Power Law
Global Error Model, Padj ≤ 0.05) are identified with thick black
borders.
Table 2. Differentially Expressed Proteins in Human Colostral Whey between Women with and without Gestational Diabetes
Mellitus
protein accessiona non-GDMb GDMb FDc Padj
d ranke
Higher in GDM
apolipoprotein D P05090 17.1 ± 12 48.1 ± 20 2.8 0.002 8
Ig heavy chain V−II region ARH-77 P06331 1.15 ± 1.7 2.04 ± 1.6 1.8 0.015 2
prostasin Q16651 4.59 ± 2 7.95 ± 4.2 1.7 0.041 5
Lower in GDM
alpha-2-HS-glycoprotein P02765 20.1 ± 8.6 9.36 ± 4.4 0.5 0.048 7
apolipoprotein A1 P02647 38.2 ± 13 16.8 ± 14 0.4 0.012 1
apolipoprotein E P02649 9.81 ± 5.3 3.21 ± 3 0.3 0.017 6
14−3−3 protein zeta/delta P63104 6.23 ± 3.3 2.11 ± 1.8 0.3 0.028 10
protein disulfide-isomerase P07237 1.36 ± 1.7 0.275 ± 0.51 0.2 0.050 9
protein DJ-1 Q99497 1.08 ± 0.79 0.097 ± 0.24 0.1 0.007 3
protein FAM3B P58499 2.77 ± 1.6 0.876 ± 1.3 0.3 0.032 4
aUniprot database identifier (http://www.uniprot.org/). bValues are reported as the mean ± standard deviation of normalized total spectra. cFold
difference, FD; of the means of normalized total spectra for GDM relative to non-GDM. dFalse discovery rate adjusted (q = 0.05) P-value for power
law global error model. eRankings are based on the absolute values of the O-PLS-DA model loadings on the LV1 for shown proteins.
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whey proteins, of which 152 were significantly regulated
between transitional and mature milk.11 In contrast to the study
reported by Gao et al., we did not use fractionation methods
prior to LC−MS/MS. However, because of the high mass
accuracy, high-resolution, and scan speed of the Q Exactive
orbitrap mass spectrometer, we were able to confidently
identify 601 proteins from the whey fraction of human milk
with a low false discovery rate at the protein and peptide level.
Additionally, we used a low peptide decoy FDR (0.27%)
compared to the protein FDR (4.9%) because there were over
470 000 peptides in this data set compared to only 601
proteins. It is common in data sets with large numbers of
identified spectra that condense to a much smaller number of
proteins to have a highly inflated protein decoy FDR compared
to the spectra or peptide decoy FDR.35
Multivariate and Statistical Analyses
In this study, we used multivariate modeling and statistical
analyses to identify differentially expressed colostral whey
proteins (i.e., proteins that were up- or down-regulated)
between women with versus without GDM. Identification of
differentially expressed proteins between these two groups
posed two major challenges: (1) limitation of the sample size
and test power precluding the identification of diagnostic
markers for GDM; and (2) overcoming the relationship
between protein expression and the time of sample collection
postpartum. By using power analysis, we have previously shown
that GDM had a large effect on the human milk glycome36 and
that the current experimental design is sufficiently powered to
detect differences in colostral whey proteins between the two
groups. However, because of the large number of proteins
measured, even proteins that display moderate effect sizes may
not yield significant results in statistical tests due to the large
penalty for multiple hypotheses tested. To reduce the FDR we
used O-PLS-DA based feature selection37 to identify the top
10% of all multivariate protein discriminants between women
with and without GDM, which were then tested using the
univariate statistical test, PLGEM. Human milk protein
composition and abundance are known to vary based on the
postpartum period.11−13 To account for this issue and ensure
that changes in colostral protein abundances were not
associated with differences in postpartum time of sample
collection, both O-PLS-DA modeling and PLGEM analyses
were conducted on NSAF protein abundances adjusted for the
time of collection postpartum using a linear model. With the
aforementioned strategy, O-PLS-DA modeling was used to
identify 27 colostral whey proteins that best discriminated
women with versus without GDM, of which 10 were identified
to be significantly differentially expressed (PLGEM Padj < 0.05)
after an adjustment was made for multiple hypothesis testing.
Gene ontology enrichment analysis and protein−protein
empirical interaction networks were used to help identify the
biological context for the noted differences in colostral whey
proteins between women with versus without GDM.
Colostral Whey Proteins Higher in GDM
One of the 10 proteins that were differentially expressed in
colostral whey from women with GDM compared to women
without GDM is the variable region of the heavy chain of an
immunoglobulin (Ig heavy chain V−II region ARH-77).
Immunoglobulins are secreted by plasma cells in the mammary
gland and throughout the body. During mature lactation,
immunoglobulins enter milk via transcytosis across mammary
epithelial cells; however, during the production of colostrum,
the tight junctions that join mammary epithelial cells are leaky,
which allows passage of immunoglobulins and white blood cells
via the paracellular pathway. That is, the immunoglobulins pass
from interstitial spaces, between the mammary epithelial cells,
and into the colostrum. Thus, in the context of the transition
from colostrum to mature milk, immunoglobulins are a marker
of the tightness of the junctions and the stage of milk
production.38 In our study, without correction for time of
postpartum milk collection, 29 of the differentially expressed
proteins were regions of immunoglobulins, which suggests that
women at the earliest and latest times of collection were in
different stages of milk production (colostrum vs transitional
milk production); however, after the adjustment for the time of
milk collection was made, only Ig heavy chain V−II region
ARH-77 was significantly higher in colostral whey from women
with GDM (Table 2). This suggests that women with GDM
may have a delayed progression from colostrum to transitional
milk production, otherwise known as a delayed lactogenesis. It
is known that obese women have delayed lactogenesis;38 yet
this protein was not significantly correlated with prepregnancy
BMI, which suggests that independent of obesity, GDM may
delay the onset of copious milk production. Furthermore, even
Figure 2. Empirical protein−protein interaction network for differentially expressed colostral whey proteins between women with and without
GDM.
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though women with GDM were disproportionally multiparous
(Table 1), have a faster onset of milk production,39 the effect of
GDM was strong enough to overcome that bias. However,
these data should be taken with caution because unlike other
immunoglobulins, this protein was in low abundance in
colostral whey and thereby susceptible to low reproducibility
and high analytical variance. Orthogonal analysis is warranted
to confirm if this protein contributes to the biological variation
in predicting maternal phenotype.
Apolipoprotein D is a lipocalin involved in lipid transport
and fluctuates during gestation and fetal development. It has
previously been shown that plasma apolipoprotein D levels
decrease during pregnancy and further decrease in women with
excessive gestational weight gain. Interestingly, plasma
apolipoprotein returned to baseline after birth more quickly
in lactating women compared to those who were not
breastfeeding.40 In our study, colostral apolipoprotein D
abundance was higher in women with GDM versus in
women without GDM. Liao et al. showed that apolipoprotein
D levels were higher in colostrum relative to mature milk.13
Interestingly, two other apolipoproteins found in human milk
(apolipoprotein A1 and apolipoprotein E) were significantly
lower in colostral whey from women with versus without
GDM. These data are supported by human trials that reported
lower plasma levels of LDL and HDL cholesterol in women
with GDM compared to healthy controls.41 Thus, it is possible
that the higher apolipoprotein D level in colostral whey from
women with GDM is due to delayed lactogenesis. However,
future human studies are warranted to test this hypothesis.
Colostral Whey Proteins Lower in GDM
Whey colostral proteins involved in de novo lipid synthesis
were uniformly lower in GDM. Differences in these proteins
were positively correlated with one another and constituted the
largest connected cluster within the empirical protein−protein
interaction network (Figure 2). Although the lipid content in
colostrum was not measured in this study, these results suggest
that women with GDM produce lipid-poor milk compared to
that of women without GDM. Morceli et al. reported 1.8-fold
lower total lipid content in colostrum from diabetic women
with hyperglycemia than from normoglycemic women.5 In mice
fed a high-fat (HF) diet, obese HF-fed mice produce lipid-poor
milk compared to that of lean HF-fed mice.42 Importantly, in
our study, none of the lipid synthesis related proteins reduced
by GDM were observed to be significantly correlated with
prepregnancy BMI, which suggests that GDM (or insulin
resistance), and not obesity per se, is associated with low-fat
milk production. Thus, we hypothesize that women with GDM
produce lipid-poor milk and that this effect is independent of
obesity.
Circulating alpha-2-HS-glycoprotein (also known as fetuin-
A), a liver-derived protein that down-regulates insulin signaling
in peripheral tissues and was recently identified as a marker of
insulin resistance, inflammation, and adiposity,43−45 was lower
in women with GDM. Serum alpha-2-HS-glycoprotein
concentrations are elevated in humans with metabolic disorders
but can also be elevated during negative energy balance (NEB),
which serves to preserve glucose utilization by peripheral
tissues. In dairy cows, alpha-2-HS-glycoprotein increases during
early lactation and causes a switch toward using fatty acids as an
energy source instead of glucose.46 Unlike cows, humans do not
heavily rely on body stores for milk synthesis but perhaps
experience mild NEB during the first days of lactation given the
energetic needs of birthing, recovery, and initiation of lactation.
In a study of the human whey proteome across lactation, alpha-
2-HS-glycoprotein did not appear to be differentially abundant
among colostrum and later stages of lactation, but subjects were
not excluded based on prepregnancy BMI or metabolic disease,
and the data was not analyzed in the context of metabolic
status.13 In our study, we found colostral whey alpha-2-HS-
glycoprotein to be lower in women with GDM relative to those
without GDM; however, colostral whey alpha-2-HS-glycopro-
tein was also negatively correlated with prepregnancy BMI;
thus, women with higher BMI also had lower levels of colostral
whey alpha-2-HS-glycoprotein. While it is not possible to
determine whether high BMI or GDM status is the driver of
lower colostrum alpha-2-HS-glycoprotein, future research is
necessary to confirm if individuals with high BMI or GDM have
a blunted response to the metabolic changes of early lactation.
Protein FAM3B, also known as PANDER (pancreatic
derived factor), a cytokine likely to be cosecreted with insulin47
by the pancreatic alpha- and beta-cells, was significantly lower
in the colostral whey from women with GDM and was not
correlated with prepregnancy BMI. While the physiological role
of FAM3B is incompletely described, its role in insulin signaling
and glucose homeostasis supports our hypothesis that GDM
impacts milk production and composition.
Herein we report that GDM had an impact on the human
colostral whey proteome. This was an observational study that
demonstrated proof of concept that alterations in whey
proteins in GDM have short-term implications for the transport
of infant nutrition. These findings should be further explored in
large prospective cohort studies that include analysis of milk
over the course of lactation and associated effects of maternal
gestational diabetes mellitus on infant nutrient status.
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